Filing Details
- Accession Number:
- 0001209191-20-037135
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-16 20:20:32
- Reporting Period:
- 2020-06-12
- Accepted Time:
- 2020-06-16 20:20:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1340652 | Chemocentryx Inc. | CCXI | Pharmaceutical Preparations (2834) | 943254365 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1423084 | J. Thomas Schall | C/O Chemocentryx, Inc. 850 Maude Avenue Mountain View CA 94043 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-06-12 | 88,753 | $14.31 | 2,357,310 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-06-12 | 88,753 | $65.08 | 2,268,557 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-06-15 | 2,000 | $14.31 | 2,270,557 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-06-15 | 2,000 | $65.04 | 2,268,557 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-06-12 | 88,753 | $0.00 | 88,753 | $14.31 |
| Common Stock | Stock Option (right to buy) | Disposition | 2020-06-15 | 2,000 | $0.00 | 2,000 | $14.31 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 37,760 | 2022-07-24 | No | 4 | M | Direct | |
| 35,760 | 2022-07-24 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $64.99 to $65.39 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $64.99 to $65.22 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- As of June 12, 2020, and prior to this transaction, the exercised options were fully vested.
- Not applicable.
Billionaire Hedge Funds
